AR032247A1 - NEW HYDRAZIDE COMPOUNDS, A PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. - Google Patents

NEW HYDRAZIDE COMPOUNDS, A PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.

Info

Publication number
AR032247A1
AR032247A1 ARP020100152A ARP020100152A AR032247A1 AR 032247 A1 AR032247 A1 AR 032247A1 AR P020100152 A ARP020100152 A AR P020100152A AR P020100152 A ARP020100152 A AR P020100152A AR 032247 A1 AR032247 A1 AR 032247A1
Authority
AR
Argentina
Prior art keywords
group
alkylene
disorders
procedure
preparation
Prior art date
Application number
ARP020100152A
Other languages
Spanish (es)
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of AR032247A1 publication Critical patent/AR032247A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)

Abstract

Compuestos de la formula (1) R-NH-A-CO-NH-NH-(W)n-Z en donde n es 0 o 1, W representa un grupo ûCO- o un grupo S(O), en donde r es 0, 1 o 2, Z representa un grupo seleccionado entre arilo, arilalquilo, heteroarilo, heteroarialquilo, todos los cuales están opcionalmente sustituidos, y alquilo, R representa un grupo seleccionado entre: Z1-T-CO-, Z1-O-T-CO-, Z1-T-O-CO-, Z1-T-S(O)q, en donde Z1 T y q son como se definieron en la descripcion. A representa un grupo alquileno, alquenileno o alquinileno, teniendo cada uno de 3 a 8 átomos de carbono, un grupo alquilenocicloalquileno, cicloalquilenoalquileno, alquilenocicloalquilenoalquileno, alquilenoarileno, arilenoalquileno o alquilenoarilenoalquileno, un grupo ûCH- en donde B1 es como se definio en la B1 descripcion, o A forma con el átomo de nitrogeno adyacente un grupo (2) como se definio en la descripcion. Medicamentos. utiles como ligando receptor del neuropéptido Y, en el tratamiento de patologías asociadas con trastornos del comportamiento alimentario, o trastornos del equilibrio energético tales como diabetes, obesidad, bulimia, anorexia nerviosa, hipertension arterial, ansiedad, depresion epilepsia, disfunciones sexuales y trastornos del sueno.Compounds of the formula (1) R-NH-A-CO-NH-NH- (W) nZ where n is 0 or 1, W represents a group ûCO- or a group S (O), where r is 0 , 1 or 2, Z represents a group selected from aryl, arylalkyl, heteroaryl, heteroaryl alkyl, all of which are optionally substituted, and alkyl, R represents a group selected from: Z1-T-CO-, Z1-OT-CO-, Z1-TO-CO-, Z1-TS (O) q, where Z1 T and q are as defined in the description. A represents an alkylene, alkenylene or alkynylene group, each having 3 to 8 carbon atoms, an alkylenecycloalkylene, cycloalkylene alkylene, alkylenecycloalkylene alkylene, alkylenearylene, arylenealkylene or alkylenearylene alkylene group, a ûCH- group where B1 is as defined in B1 , or A with the adjacent nitrogen atom forms a group (2) as defined in the description. Medicines. Useful as a neuropeptide receptor ligand Y, in the treatment of pathologies associated with eating disorders, or disorders of energy balance such as diabetes, obesity, bulimia, anorexia nervosa, arterial hypertension, anxiety, epilepsy depression, sexual dysfunctions and sleep disorders .

ARP020100152A 2001-01-17 2002-01-17 NEW HYDRAZIDE COMPOUNDS, A PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. AR032247A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200100105A ES2187334B1 (en) 2001-01-17 2001-01-17 NEW DERIVATIVES OF HYDRAZIDE, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.

Publications (1)

Publication Number Publication Date
AR032247A1 true AR032247A1 (en) 2003-10-29

Family

ID=8496424

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020100152A AR032247A1 (en) 2001-01-17 2002-01-17 NEW HYDRAZIDE COMPOUNDS, A PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.

Country Status (3)

Country Link
AR (1) AR032247A1 (en)
ES (1) ES2187334B1 (en)
WO (1) WO2002057220A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5187901B2 (en) * 2006-08-30 2013-04-24 塩野義製薬株式会社 Hydrazine amide derivatives
TWI490214B (en) 2008-05-30 2015-07-01 艾德克 上野股份有限公司 Benzene or thiophene derivative and use thereof as vap-1 inhibitor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000027843A1 (en) * 1998-11-09 2000-05-18 Smithkline Beecham Corporation Ccr-3 receptor antagonists
ES2161594B1 (en) * 1998-12-17 2003-04-01 Servier Lab NEW DERIVATIVES OF HYDRAZIDE, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.

Also Published As

Publication number Publication date
WO2002057220A1 (en) 2002-07-25
ES2187334A1 (en) 2003-06-01
ES2187334B1 (en) 2004-09-16

Similar Documents

Publication Publication Date Title
NZ501849A (en) Carbonyl hydrazino derivatives further substituted by carbamate or sulphonamide groups
EA200200270A1 (en) NEW SPIRING COMPOUNDS
HUP0104773A2 (en) 2,3,4,4a-tetrahydro-1h-pyrazino(1,2-a)quinoxalin-5(6h)one derivates being 5ht2c agonists, process for their preparation and medicaments containing them
MXPA05003715A (en) Modulation of anxiety through blockade of anandamide hydrolysis.
EA200300428A1 (en) ANTAGONISTS OF METABOTROPIC GLUTAMAT RECEPTORS
KR20040048393A (en) Novel amides compounds and the pharmaceutical compositions containing the same
DE69408962T2 (en) Naphthalene derivatives with affinity for melatonin receptors, processes for their preparation and pharmaceutical compositions containing them
MA28422B1 (en) N- (1,5-DIPHENYL-1H-PYRAZOL-3-YL) SULFONAMIDE DERIVATIVES WITH AFFINITY FOR CB1 RECEPTORS
Manoury et al. Synthesis and antihypertensive activity of a series of 4-amino-6, 7-dimethoxyquinazoline derivatives
TNSN07041A1 (en) N- (1H-INDOLYL) -I H-INDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
NO20033145D0 (en) Purine derivatives as purinergic receptor antagonists
ES2247668T3 (en) NEW NAFTALENO COMPOUNDS, THE PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
AR032247A1 (en) NEW HYDRAZIDE COMPOUNDS, A PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
WO2006112742A3 (en) PROCESS FOR PREPARATION OF 13,14-DIHYDRO-PGF2α DERIVATIVES
JP2006503090A (en) Novel N-hydroxythiourea, urea and amide compounds and pharmaceutical compositions comprising these
Lee et al. N-(3-Acyloxy-2-benzylpropyl)-N′-dihydroxytetrahydrobenzazepine and tetrahydroisoquinoline thiourea analogues as vanilloid receptor ligands
MA30222B1 (en) NOVEL POLYSUBSTITUTED PYRIDINYLAMINOALKYLENE AND PYRIDINYLOXYALKYLENE CYCLOPROPANAMINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO2006098554A1 (en) Novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and a pharmaceutical composition containing the same
DK697988A (en) CYCLIC CARBOHYDRIDES WITH AN AMINOAL COOL SIDE CHAIN
AR031726A1 (en) NEW AMINOTRIAZOLONA COMPOUNDS, A PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM
NO20065958L (en) Tetrasubstituted imidazole derivatives as cannabinoid CB1 receptor modulators with a high CB1 / CB2 receptor subtype selectivity
Maruyama et al. Discovery of novel thiourea derivatives as potent and selective β3-adrenergic receptor agonists
RU2005107587A (en) Antidepressants-indolalkyl derivatives of benzodioxane-methylamines condensed with heterocycles
CO5160333A1 (en) TETRAZINE DERIVATIVES PESTICIDLY ACTIVE AND COMPOSITION THAT CONTAINS THEM
MXPA05012572A (en) 5-h -benzo [d] naphth [2, 1-b] azepine derivative as selective d1.

Legal Events

Date Code Title Description
FB Suspension of granting procedure